Dr Achutanand Lal Karn, Faculty of Cardiology, National Medical College Teaching Hospital (NMCTH), Birgunj-18, Nepal; E-mail:
Mymensingh Med J. 2021 Jan;30(1):202-207.
Identifying the reperfusion success angiographically and predicting the prognosis is important following the Percutaneous Coronary Intervention (PCI). Though the assessment of successful PCI is still done by Thrombolysis in myocardial infarction (TIMI) Flow Grades (TFG), TIMI Myocardial perfusion grade (TMPG) is also a well accepted method of predicting outcomes in acute coronary syndrome (ACS) patients. Angiographic perfusion score (APS) that integrates both epicardial (TFG) and Myocardial tissue level perfusion (TMPG) before and after percutaneous coronary intervention may accurately measure the reperfusion success and predict Major adverse cardiac events (MACE) in ACS without any thrombolytic pre-treatment. This observational study was done in the Cardiology department of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from January 2014 to July 2015. With the appropriate methodological and statistical analysis, the data was drawn from the sample size of 60 eligible patients. APS (0-12) and post-procedure TMPG (0-3) alone were assessed following PCI in all eligible patients and then compared for the reperfusion success and short term (within 30days) clinical outcomes of MACE. Reperfusion success was identified significantly more in APS group versus TMPG alone (STEMI: 69.5% vs. 21.7% (p<0.05); Non STEMI/UA, late perfusion: 81.8% vs. 30.3% (p<0.05) respectively. A significantly lower incidence of MACE was found in the Full as compared to the Failed APS group (2.3% vs. 100%) (p<0.001). But no differences were observed between TMPG 1-3 (12.5%; 3.4% & 6.7%, respectively) (p=NS). Compared to TMPG alone, APS is a better reflector of reperfusion success as well as favorable predictor for short term clinical risk following PCI done during the index hospitalization in ACS.
经皮冠状动脉介入治疗(PCI)后,明确再灌注是否成功并预测预后十分重要。虽然 PCI 成功的评估仍采用心肌梗死溶栓治疗(TIMI)血流分级(TFG),但 TIMI 心肌灌注分级(TMPG)也是预测急性冠脉综合征(ACS)患者预后的一种公认方法。血管造影灌注评分(APS)综合了 PCI 前后心外膜(TFG)和心肌组织水平灌注(TMPG),可准确测量再灌注是否成功,并预测 ACS 患者的主要不良心脏事件(MACE),且无需任何溶栓预处理。本观察性研究于 2014 年 1 月至 2015 年 7 月在孟加拉国达卡的 Bangabandhu Sheikh Mujib 医科大学(BSMMU)心内科进行。通过适当的方法学和统计学分析,从 60 名符合条件的患者中抽取了数据。对所有符合条件的患者在 PCI 后单独评估 APS(0-12)和术后 TMPG(0-3),然后比较再灌注成功情况和短期(30 天内)MACE 的临床结果。与单独 TMPG 相比,APS 组的再灌注成功率更高(STEMI:69.5%比 21.7%(p<0.05);非 STEMI/UA,晚期灌注:81.8%比 30.3%(p<0.05)。与失败的 APS 组相比,完全 APS 组的 MACE 发生率显著降低(2.3%比 100%)(p<0.001)。但 TMPG 1-3 组之间未见差异(分别为 12.5%、3.4%和 6.7%)(p=NS)。与单独 TMPG 相比,APS 是再灌注成功的更好反映,也是 ACS 患者 PCI 期间住院期间短期临床风险的有利预测指标。